Efficacy and safety of 30-Mg fimasartan for the treatment of patients with mild to moderate hypertension: An 8-week, multicenter, randomized, double-blind, phase III clinical study

Jong Chan Youn, Sang Hyun Ihm, Jang Ho Bae, Seong-Mi Park, Dong Woon Jeon, Byung Chun Jung, Tae Ho Park, Nae Hee Lee, Jong Min Song, Young Won Yoon, Eun Seok Shin, Ki Chul Sung, In Hyun Jung, Wook Bum Pyun, Seung Jae Joo, Woo Jung Park, Jin Ho Shin, Seok Min Kang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose The standard 60-mg dose of fimasartan, a newly developed selective angiotensin II receptor blocker, is effective and safe for use in patients with mild to moderate hypertension. This study aimed to compare the efficacy and safety of low-dose (30 mg) fimasartan and placebo or valsartan (80 mg) for 8 weeks in patients with mild to moderate hypertension.

Methods In this randomized trial, 293 patients (219 men; mean age, 54.24 [9.77] years) with mild to moderate hypertension were enrolled. After randomization to receive 30-mg fimasartan (n = 115), placebo (n = 117), or 80-mg valsartan (n = 61), the treatment dose was kept constant without dose escalation for 8 weeks. The primary end point was improvement in sitting diastolic blood pressure (SiDBP) from baseline to 8 weeks that was compared between treatments with low-dose fimasartan and placebo. The secondary end point was the overall efficacy and safety of low-dose fimasartan compared with that of placebo or valsartan.

Findings At week 8, SiDBP changed by -9.93 (8.86) mm Hg in the fimasartan group and by -2.08 (9.47) mm Hg in the placebo group, which indicated significant antihypertensive efficacy (P < 0.0001). Efficacy was shown at week 4 as measured by SiDBP (-9.96 [7.73] vs -2.27 [7.85] mm Hg; P < 0.0001) or sitting systolic blood pressure (SiSBP) (-16.18 [14.44] vs -1.95 [13.48] mmHg; P < 0.0001) and at week 8 as determined by SiSBP (-15.35 [16.63] vs -2.30 [14.91] mm Hg; P < 0.0001). The fimasartan group exhibited more potent antihypertensive efficacy than the valsartan group both at week 4 (SiDBP, -9.96 [7.73] vs -6.53 [9.58] mm Hg [P = 0.0123]; SiSBP, -16.18 [14.4] vs -7.65 [12.89] mm Hg [P = 0.0002]) and at week 8 (SiDBP, -9.93 [8.86] vs -5.47 [8.96] mm Hg [P = 0.0021]; SiSBP, -15.35 [16.63] vs -7.49 [13.68] mm Hg [P = 0.0021]). Most treatment-emergent adverse events (TEAEs) were mild (89 of 95), and there were no serious TEAEs. The incidence of TEAEs was 19.1% in the fimasartan group, 22.6% in the placebo group, and 13.6% in the valsartan group, with no significant differences.

Implications Low-dose fimasartan (30 mg) was well tolerated during the study period with no significant TEAEs. Low-dose fimasartan had an effective blood pressure-lowering effect that was greater than that of 80-mg valsartan in patients with mild to moderate hypertension. ClinicalTrials.gov identifier: NCT01672476.

Original languageEnglish
Pages (from-to)1412-1421
Number of pages10
JournalClinical Therapeutics
Volume36
Issue number10
DOIs
Publication statusPublished - 2014 Nov 10

Fingerprint

Valsartan
Blood Pressure
Hypertension
Safety
Therapeutics
Placebos
Clinical Studies
fimasartan
Antihypertensive Agents
Angiotensin Receptor Antagonists
Random Allocation

Keywords

  • fimasartan
  • hypertension
  • placebo
  • valsartan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Efficacy and safety of 30-Mg fimasartan for the treatment of patients with mild to moderate hypertension : An 8-week, multicenter, randomized, double-blind, phase III clinical study. / Youn, Jong Chan; Ihm, Sang Hyun; Bae, Jang Ho; Park, Seong-Mi; Jeon, Dong Woon; Jung, Byung Chun; Park, Tae Ho; Lee, Nae Hee; Song, Jong Min; Yoon, Young Won; Shin, Eun Seok; Sung, Ki Chul; Jung, In Hyun; Pyun, Wook Bum; Joo, Seung Jae; Park, Woo Jung; Shin, Jin Ho; Kang, Seok Min.

In: Clinical Therapeutics, Vol. 36, No. 10, 10.11.2014, p. 1412-1421.

Research output: Contribution to journalArticle

Youn, JC, Ihm, SH, Bae, JH, Park, S-M, Jeon, DW, Jung, BC, Park, TH, Lee, NH, Song, JM, Yoon, YW, Shin, ES, Sung, KC, Jung, IH, Pyun, WB, Joo, SJ, Park, WJ, Shin, JH & Kang, SM 2014, 'Efficacy and safety of 30-Mg fimasartan for the treatment of patients with mild to moderate hypertension: An 8-week, multicenter, randomized, double-blind, phase III clinical study', Clinical Therapeutics, vol. 36, no. 10, pp. 1412-1421. https://doi.org/10.1016/j.clinthera.2014.07.004
Youn, Jong Chan ; Ihm, Sang Hyun ; Bae, Jang Ho ; Park, Seong-Mi ; Jeon, Dong Woon ; Jung, Byung Chun ; Park, Tae Ho ; Lee, Nae Hee ; Song, Jong Min ; Yoon, Young Won ; Shin, Eun Seok ; Sung, Ki Chul ; Jung, In Hyun ; Pyun, Wook Bum ; Joo, Seung Jae ; Park, Woo Jung ; Shin, Jin Ho ; Kang, Seok Min. / Efficacy and safety of 30-Mg fimasartan for the treatment of patients with mild to moderate hypertension : An 8-week, multicenter, randomized, double-blind, phase III clinical study. In: Clinical Therapeutics. 2014 ; Vol. 36, No. 10. pp. 1412-1421.
@article{737fd6cd403d4ec99c42e85bdb6e4c37,
title = "Efficacy and safety of 30-Mg fimasartan for the treatment of patients with mild to moderate hypertension: An 8-week, multicenter, randomized, double-blind, phase III clinical study",
abstract = "Purpose The standard 60-mg dose of fimasartan, a newly developed selective angiotensin II receptor blocker, is effective and safe for use in patients with mild to moderate hypertension. This study aimed to compare the efficacy and safety of low-dose (30 mg) fimasartan and placebo or valsartan (80 mg) for 8 weeks in patients with mild to moderate hypertension.Methods In this randomized trial, 293 patients (219 men; mean age, 54.24 [9.77] years) with mild to moderate hypertension were enrolled. After randomization to receive 30-mg fimasartan (n = 115), placebo (n = 117), or 80-mg valsartan (n = 61), the treatment dose was kept constant without dose escalation for 8 weeks. The primary end point was improvement in sitting diastolic blood pressure (SiDBP) from baseline to 8 weeks that was compared between treatments with low-dose fimasartan and placebo. The secondary end point was the overall efficacy and safety of low-dose fimasartan compared with that of placebo or valsartan.Findings At week 8, SiDBP changed by -9.93 (8.86) mm Hg in the fimasartan group and by -2.08 (9.47) mm Hg in the placebo group, which indicated significant antihypertensive efficacy (P < 0.0001). Efficacy was shown at week 4 as measured by SiDBP (-9.96 [7.73] vs -2.27 [7.85] mm Hg; P < 0.0001) or sitting systolic blood pressure (SiSBP) (-16.18 [14.44] vs -1.95 [13.48] mmHg; P < 0.0001) and at week 8 as determined by SiSBP (-15.35 [16.63] vs -2.30 [14.91] mm Hg; P < 0.0001). The fimasartan group exhibited more potent antihypertensive efficacy than the valsartan group both at week 4 (SiDBP, -9.96 [7.73] vs -6.53 [9.58] mm Hg [P = 0.0123]; SiSBP, -16.18 [14.4] vs -7.65 [12.89] mm Hg [P = 0.0002]) and at week 8 (SiDBP, -9.93 [8.86] vs -5.47 [8.96] mm Hg [P = 0.0021]; SiSBP, -15.35 [16.63] vs -7.49 [13.68] mm Hg [P = 0.0021]). Most treatment-emergent adverse events (TEAEs) were mild (89 of 95), and there were no serious TEAEs. The incidence of TEAEs was 19.1{\%} in the fimasartan group, 22.6{\%} in the placebo group, and 13.6{\%} in the valsartan group, with no significant differences.Implications Low-dose fimasartan (30 mg) was well tolerated during the study period with no significant TEAEs. Low-dose fimasartan had an effective blood pressure-lowering effect that was greater than that of 80-mg valsartan in patients with mild to moderate hypertension. ClinicalTrials.gov identifier: NCT01672476.",
keywords = "fimasartan, hypertension, placebo, valsartan",
author = "Youn, {Jong Chan} and Ihm, {Sang Hyun} and Bae, {Jang Ho} and Seong-Mi Park and Jeon, {Dong Woon} and Jung, {Byung Chun} and Park, {Tae Ho} and Lee, {Nae Hee} and Song, {Jong Min} and Yoon, {Young Won} and Shin, {Eun Seok} and Sung, {Ki Chul} and Jung, {In Hyun} and Pyun, {Wook Bum} and Joo, {Seung Jae} and Park, {Woo Jung} and Shin, {Jin Ho} and Kang, {Seok Min}",
year = "2014",
month = "11",
day = "10",
doi = "10.1016/j.clinthera.2014.07.004",
language = "English",
volume = "36",
pages = "1412--1421",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "10",

}

TY - JOUR

T1 - Efficacy and safety of 30-Mg fimasartan for the treatment of patients with mild to moderate hypertension

T2 - An 8-week, multicenter, randomized, double-blind, phase III clinical study

AU - Youn, Jong Chan

AU - Ihm, Sang Hyun

AU - Bae, Jang Ho

AU - Park, Seong-Mi

AU - Jeon, Dong Woon

AU - Jung, Byung Chun

AU - Park, Tae Ho

AU - Lee, Nae Hee

AU - Song, Jong Min

AU - Yoon, Young Won

AU - Shin, Eun Seok

AU - Sung, Ki Chul

AU - Jung, In Hyun

AU - Pyun, Wook Bum

AU - Joo, Seung Jae

AU - Park, Woo Jung

AU - Shin, Jin Ho

AU - Kang, Seok Min

PY - 2014/11/10

Y1 - 2014/11/10

N2 - Purpose The standard 60-mg dose of fimasartan, a newly developed selective angiotensin II receptor blocker, is effective and safe for use in patients with mild to moderate hypertension. This study aimed to compare the efficacy and safety of low-dose (30 mg) fimasartan and placebo or valsartan (80 mg) for 8 weeks in patients with mild to moderate hypertension.Methods In this randomized trial, 293 patients (219 men; mean age, 54.24 [9.77] years) with mild to moderate hypertension were enrolled. After randomization to receive 30-mg fimasartan (n = 115), placebo (n = 117), or 80-mg valsartan (n = 61), the treatment dose was kept constant without dose escalation for 8 weeks. The primary end point was improvement in sitting diastolic blood pressure (SiDBP) from baseline to 8 weeks that was compared between treatments with low-dose fimasartan and placebo. The secondary end point was the overall efficacy and safety of low-dose fimasartan compared with that of placebo or valsartan.Findings At week 8, SiDBP changed by -9.93 (8.86) mm Hg in the fimasartan group and by -2.08 (9.47) mm Hg in the placebo group, which indicated significant antihypertensive efficacy (P < 0.0001). Efficacy was shown at week 4 as measured by SiDBP (-9.96 [7.73] vs -2.27 [7.85] mm Hg; P < 0.0001) or sitting systolic blood pressure (SiSBP) (-16.18 [14.44] vs -1.95 [13.48] mmHg; P < 0.0001) and at week 8 as determined by SiSBP (-15.35 [16.63] vs -2.30 [14.91] mm Hg; P < 0.0001). The fimasartan group exhibited more potent antihypertensive efficacy than the valsartan group both at week 4 (SiDBP, -9.96 [7.73] vs -6.53 [9.58] mm Hg [P = 0.0123]; SiSBP, -16.18 [14.4] vs -7.65 [12.89] mm Hg [P = 0.0002]) and at week 8 (SiDBP, -9.93 [8.86] vs -5.47 [8.96] mm Hg [P = 0.0021]; SiSBP, -15.35 [16.63] vs -7.49 [13.68] mm Hg [P = 0.0021]). Most treatment-emergent adverse events (TEAEs) were mild (89 of 95), and there were no serious TEAEs. The incidence of TEAEs was 19.1% in the fimasartan group, 22.6% in the placebo group, and 13.6% in the valsartan group, with no significant differences.Implications Low-dose fimasartan (30 mg) was well tolerated during the study period with no significant TEAEs. Low-dose fimasartan had an effective blood pressure-lowering effect that was greater than that of 80-mg valsartan in patients with mild to moderate hypertension. ClinicalTrials.gov identifier: NCT01672476.

AB - Purpose The standard 60-mg dose of fimasartan, a newly developed selective angiotensin II receptor blocker, is effective and safe for use in patients with mild to moderate hypertension. This study aimed to compare the efficacy and safety of low-dose (30 mg) fimasartan and placebo or valsartan (80 mg) for 8 weeks in patients with mild to moderate hypertension.Methods In this randomized trial, 293 patients (219 men; mean age, 54.24 [9.77] years) with mild to moderate hypertension were enrolled. After randomization to receive 30-mg fimasartan (n = 115), placebo (n = 117), or 80-mg valsartan (n = 61), the treatment dose was kept constant without dose escalation for 8 weeks. The primary end point was improvement in sitting diastolic blood pressure (SiDBP) from baseline to 8 weeks that was compared between treatments with low-dose fimasartan and placebo. The secondary end point was the overall efficacy and safety of low-dose fimasartan compared with that of placebo or valsartan.Findings At week 8, SiDBP changed by -9.93 (8.86) mm Hg in the fimasartan group and by -2.08 (9.47) mm Hg in the placebo group, which indicated significant antihypertensive efficacy (P < 0.0001). Efficacy was shown at week 4 as measured by SiDBP (-9.96 [7.73] vs -2.27 [7.85] mm Hg; P < 0.0001) or sitting systolic blood pressure (SiSBP) (-16.18 [14.44] vs -1.95 [13.48] mmHg; P < 0.0001) and at week 8 as determined by SiSBP (-15.35 [16.63] vs -2.30 [14.91] mm Hg; P < 0.0001). The fimasartan group exhibited more potent antihypertensive efficacy than the valsartan group both at week 4 (SiDBP, -9.96 [7.73] vs -6.53 [9.58] mm Hg [P = 0.0123]; SiSBP, -16.18 [14.4] vs -7.65 [12.89] mm Hg [P = 0.0002]) and at week 8 (SiDBP, -9.93 [8.86] vs -5.47 [8.96] mm Hg [P = 0.0021]; SiSBP, -15.35 [16.63] vs -7.49 [13.68] mm Hg [P = 0.0021]). Most treatment-emergent adverse events (TEAEs) were mild (89 of 95), and there were no serious TEAEs. The incidence of TEAEs was 19.1% in the fimasartan group, 22.6% in the placebo group, and 13.6% in the valsartan group, with no significant differences.Implications Low-dose fimasartan (30 mg) was well tolerated during the study period with no significant TEAEs. Low-dose fimasartan had an effective blood pressure-lowering effect that was greater than that of 80-mg valsartan in patients with mild to moderate hypertension. ClinicalTrials.gov identifier: NCT01672476.

KW - fimasartan

KW - hypertension

KW - placebo

KW - valsartan

UR - http://www.scopus.com/inward/record.url?scp=84908305343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908305343&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2014.07.004

DO - 10.1016/j.clinthera.2014.07.004

M3 - Article

C2 - 25092393

AN - SCOPUS:84908305343

VL - 36

SP - 1412

EP - 1421

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 10

ER -